Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Participants With Chronic Hepatitis C - An Observational Study in Greece
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 23 Aug 2017
At a glance
- Drugs Dasabuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors AbbVie
- 27 Dec 2016 Planned End Date changed from 1 Oct 2017 to 1 Nov 2017.
- 27 Dec 2016 Planned primary completion date changed from 1 Oct 2017 to 1 Nov 2017.
- 27 Dec 2016 Status changed from recruiting to active, no longer recruiting.